| Literature DB >> 16419419 |
Abstract
Corticosteroids are used as first-line treatment for many ocular inflammatory conditions. The risk of adverse effects, however, necessitates conversion to steroid-sparing immunomodulatory therapy (IMT) for disease that is recurrent, chronic, or poorly responsive to treatment. Combination drug treatments with multiple agent 'recipes' are also considered. Immunomodulatory agents include the broad categories of antimetabolites (azathioprine, methotrexate, mycophenolate mofetil), alkylating agents (cyclophosphamide, chlorambucil), T-cell inhibitors (cyclosporine, tacrolimus), and cytokines (interferon alfa). This article reviews and summarizes the evidence for IMT agent use in the treatment of various forms of ocular inflammation.Entities:
Mesh:
Substances:
Year: 2005 PMID: 16419419 DOI: 10.1080/09273940590951034
Source DB: PubMed Journal: Ocul Immunol Inflamm ISSN: 0927-3948 Impact factor: 3.070